Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 5585 results found. Search for [ India Pharma ]

Results 60 to 80 of 5585
BusinessToday.In
May 30, 2021
Patel said vaccine developement takes place in phases, starting with adults, followed by 12-18 years age group and then for under 12 years children.


BusinessToday.In
May 29, 2021
The Delhi government has floated the global tender to scale up the COVID-19 vaccination drive in the national capital


PTI
May 29, 2021
The health ministry said the Centre is regularly interacting with national and international manufacturers like Pfizer, Moderna to make vaccines available in the country


PTI
May 29, 2021
Hyderabad-based Bharat Biotech said the timeline for manufacturing, testing and release for a batch of Covaxin is around 120 days, depending on the technology framework and regulatory guidelines to be met


PB Jayakumar
May 28, 2021
While official data shows 2.1 crore doses of Covaxin had been administered across the country till Thursday, based on statements from Bharat Biotech and Centre, at least 6 crore doses should have been produced and available for vaccination


BusinessToday.In
May 28, 2021
Nifty closed 97 points higher at 15,435 against previous close of 15,337 and Sensex ended 307.66 points higher at 51,422


BusinessToday.In
May 28, 2021
Revenue from operations grew 4 per cent to Rs 8,522.98 crore in the March-ended quarter against Rs 8,184.94 crore a year ago


Akshaya Nath
May 28, 2021
If functional, the IVC has the capacity to produce one billion vaccines annually. This means it can cater to a large part of the demand of Tamil Nadu as well as the rest of the country


PB Jayakumar
May 28, 2021
COVAX has delivered over 70 million doses to 126 countries around the world since February, in the largest and most complex rollout of vaccines in history


BusinessToday.In
May 28, 2021
\"Our next step is that we're going to offer vaccination to our school students, the teenagers, following which it'll be open season for everyone in Singapore,\" said Foreign Minister Vivian Balakrishnan


BusinessToday.In
May 28, 2021
The MoU stated that Hester will provide complete infrastructure to manufacture the indigenously developed anti-COVID vaccine


BusinessToday.In
May 28, 2021
Stocks in news: Sun Pharma, TCS, Eicher Motors, NLC India, UCO Bank, NLC India, Navneet Education, Dixon Technologies and more


BusinessToday.In
New Delhi, May 27, 2021
US pharma giant Pfizer on Wednesday told the central government that its COVID-19 vaccine is 'highly effective' against the COVID-19 variant that is prevalent in India. The company also reportedly sought fast-track approval of its vaccine. Pfizer also added that its vaccine is suitable for everyone aged 12 years or above and can be stored for a month at 2-8 degrees. On the other hand, Moderna is in talks with Cipla and other Indian pharma firms to launch its single-dose COVID-19 vaccine in India by next year. Cipla has already expressed interest in procuring 5 crore doses from Moderna for 2022. But, when will these vaccines be available in India and why India needs them? Watch the video to know.Also Read: Pfizer seeks fast-track approval for vaccine; says it's 'highly effective' against India COVID-19 variant


Ashutosh Kumar
May 27, 2021
Along with the GST slab change on shipping MRO, the council may also amend the place of supply rules to incentivise foreign vessels opt for tax free MRO services in the country


Reuters
May 27, 2021
India has been inoculating its people with the AstraZeneca vaccine produced locally at the Serum Institute, Covaxin made by local firm Bharat Biotech, and has begun rolling out Russia's Sputnik V


PB Jayakumar
May 27, 2021
Sotrovimab will be available for appropriate patients diagnosed with COVID-19 in the US in the coming weeks and discussions with global regulators regarding authorisations in additional countries continue to advance, said GSK


BusinessToday.In
May 27, 2021
Two vaccines developed by China National Biotech Group Co, which is a unit of Sinopharm, showed the efficacy of 72.8 per cent and 78.1 per cent, respectively. The current efficacy rate largely falls in line with Sinopharm's previous claims


PTI
May 27, 2021
We should procure this vaccine asap for our children, Kejriwal tweeted, citing a news story on fast-track approval sought by the company


Reuters
May 27, 2021
Syngene, majority owned by biopharmaceutical company Biocon Ltd, is one of the seven Indian companies that have licensed remdesivir from U.S.-based Gilead Sciences Inc


BusinessToday.In
May 27, 2021
Pfizer told Indian authorities that its vaccine has demonstrated \"high effectiveness\" against the COVID-19 variant prevalent in India and on people of Indian ethnicity or nationality


PAGES 4 OF 280  12345